A carregar...

Dimebon disappointment

Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this study there were improvements over 6 months in all endpoints (cognitive, global, dai...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Jones, Roy W
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2983434/
https://ncbi.nlm.nih.gov/pubmed/20836898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/alzrt49
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!